Brief: GNI Group gets IND clearance by FDA for liver fibrosis treatment

GNI

09/10/2017 21:00

Oct 9 (Reuters) - GNI Group Ltd  2160.T  
    * GNI Group announces clearance of investigational new drug 
(IND) by FDA for F351 clinical trials in the treatment of liver 
fibrosis 
    * GNI Group ltd does not expect submission will impact 
financial results for year ending December 31, 2017 
    * GNI USA intends to initiate necessary procedures to start 
a phase I open label study in U.S. in early 2018 
    * Preliminary results are expected within 2018 
 
Source text for Eikon:  ID:nBwwL2Nja  
Further company coverage:  2160.T  
 
 ((bangalore.newsroom@thomsonreuters.com;))